ASH 2010 - Orlando - CML - Chronic Myeloid Leukemia




ASH 2010 Report: A new era in first line CML treatment coming up?
December 15, 2010 , CML Advocates Network

Abstracts and notes on CML presentations ASH 2010 Orlando
December 8, 2010, spirit-cml.org

Dasatinib moves ahead of imatinib as front-line therapy for newly diagnosed CML in chronic phase
December 7, 2010, CancerNetwork.com

Nilotinib exerts positive effect in early chronic phase Ph+ CML
December 7, 2010, CancerNetwork.com

Persistence of BCR-ABL-Expressing leukemic stem cells in chronic myeloid leukemia (CML) patients in complete remission with undetectable molecular disease
December 7, 2010, ASH 2010

ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study
December 7, 2010, Thepharmaletter

ASH: New CML Drug Still Beating Out Its Predecessor
December 7, 2010, Medpage Today

New Help for More CML Patients(with Dr. Jorges E. Cortes)                                                              VIDEO
December 6, 2010, Patient Power

Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat

ASH: Early assessment of molecular response identified increased risk for treatment failure in CML
December 6, 2010, Hemonctoday

ASH 2010: JAK2-Mediated Extrinsic Survival of CML Stem Cells: Exploring the Potential Combination of BCR-ABL and JAK2 Inhibitors In Vivo
December 6, 2010, ASH2010

ASH2010 - The ponatinib, a molecule with many potential patients resistant(with Dr. Jorge Cortes)
December 6, 2010, Médecine Plus                                                                                                     VIDEO

ASH2010 - Hedgehog inhibitor that inhibits proliferation of self-leukemic hematopoietic stem cells in long term (with Dr. Bin Zhang) VIDEO
December 6, 2010, Médecine Plus

ASH2010- New evidence of the superiority of nilotinib in imatinib (with Dr. Tim Hugues)                    VIDEO
December 2010, Médecine Plus

ASH2010 - Bosutinib versus imatiniB (with Dr. Carlo Gambacorti- Passerini)                                       VIDEO
December 2010, Médecine Plus

Distinct Impact of Imatinib on Growth In Prepubertal and Pubertal Children with Chronic Myeloid Leukemia
December 5, 2010, ASH2010

Provocative Questions For CML Patients and Their Doctors(with Dr. Talpaz)                                       VIDEO
December 5, 2010,  Patient Power 

Do 3rd Generation Medicines Lie Ahead for CML?(with Dr. Neil Shah )                                                 VIDEO
December 4, 2010,  Patient Power

Progress in Chronic Leukemias(with Dr. Alison Loren)                                                                          VIDEO
December 4, 2010, Patient Power 

Breakthrough Therapies and a New Gene Target Advance the Treatment and Understanding of Hard-to-Treat Leukemias
December 4, 2010, Hematology.org

Nilotinib associated with stable outcomes in Ph+CML
December 4, 2010,  Hemonctoday

ASH 2010: Ponatinib for refractory chronic myelogenous leukaemia
December 4, 2010, EcancerMedicalScience
Reporting from ASH 2010
Interview with Dr. Cortes, Dr. Hugues, Dr. Mauro, Dr. Mustjoki, Dr. Passerini, and Dr. Shah.
by the CML Society of Canada                                                                                VIDEOs


ASH 2010 - Orlando- by Prof. Stephen O'brien

52nd ASH Annual Meeting and Exposition - Program for CML

Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster I
Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster II

Chronic Myeloid Leukemia - Therapy: Poster I
Chronic Myeloid Leukemia - Therapy: Poster II
Chronic Myeloid Leukemia - Therapy: Poster III

Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: CML Stem Cell/Progenitor Biology
Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Novel Molecular Mechanisms and Targets in CML


Chronic Myeloid Leukemia - Therapy: Optimizing Treatment Outcome
Chronic Myeloid Leukemia - Therapy: Optimizing Front-Line Therapy in CML
Chronic Myeloid Leukemia - Therapy: Rethinking Therapy Targets and Prognostic Factors
Chronic Myeloid Leukemia - Therapy: Management of Imatinib-Resistant CML